{
  "source": "PA-Notification-Korlym.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1056-14\nProgram Prior Authorization/Notification\nMedication Korlym® (mifepristone)\nP&T Approval Date 4/2012, 4/2013, 4/2014, 4/2015, 2/2016, 12/2016, 3/2017, 3/2018, 3/2019,\n3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nKorlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia\nsecondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have\ntype 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for\nsurgery.\nKorlym is not indicated for the treatment of type 2 diabetes mellitus unrelated to endogenous\nCushing’s syndrome.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Korlym will be approved based on all of the following criteria:\na. Diagnosis of endogenous Cushing’s syndrome (i.e., hypercortisolism is not a result of\nchronic administration of high dose glucocorticoids)\n-AND-\nb. One of the following:\n(1) Diagnosis of type 2 diabetes mellitus\n(2) Diagnosis of glucose intolerance\n-AND-\nc. One of the following:\n(1) Patient has failed surgery\n(2) Patient is not a candidate for surgery\nAuthorization will be issued for 12 months.\nB. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n1\n1. Korlym will be approved based on the following criterion:\na. Documentation of a positive clinical response while on Korlym therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or thera",
    " and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Korlym [Package Insert]. Redwood City, CA: Corcept Therapeutics, Inc.; September 2024.\nProgram Prior Authorization/Notification - Korlym (mifepristone)\nChange Control\n4/2014 Annual review with update to background, reauthorization criteria and\nreferences.\n4/2015 Annual review with update to reference.\n2/2016 Annual review. Removed ‘not pregnant’ from criteria.\n12/2016 Annual review. Updated formatting, background and references.\n3/2017 Annual review with no changes to coverage criteria. Updated background\nand references.\n3/2018 Annual review with no changes to coverage criteria. Updated references.\n3/2019 Annual review with no changes.\n3/2020 Annual review with no changes to coverage criteria. Updated references.\n3/2021 Annual review with no changes to coverage criteria.\n3/2022 Annual review. No changes.\n3/2023 Annual review with no changes to coverage criteria. Added state mandate\nfootnote.\n3/2024 Annual review. Updated approval duration of coverage criteria to 12\nmonths. Updated reauthorization criteria.\n3/2025 Annual review with no changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}